Robyn Karnauskas Analyst Performance

Robyn Karnauskas is a stock analyst at Truist Financial focused in the medical sector, covering 26 publicly traded companies. Over the past year, Robyn Karnauskas has issued 2 stock ratings, including buy and hold recommendations. While full access to Robyn Karnauskas' proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robyn Karnauskas' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

98 Last 11 Years

Buy Recommendations

88.42% 84 Buy Ratings

Companies Covered

26 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	88.4%	84 ratings
Hold	10.5%	10 ratings
Sell	1.1%	1 ratings

Out of 95 total stock ratings issued by Robyn Karnauskas at Truist Financial, the majority (88.4%) have been Buy recommendations, followed by 10.5% Hold and 1.1% Sell.

Best & Worst Calls

• Best Call

  000.0%

  IMVT

  Dec 2021

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  DCPH

  Apr 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	80.8% of companies on NASDAQ	21 companies
NYSE	19.2% of companies on NYSE	5 companies

Robyn Karnauskas, an analyst at Truist Financial, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 24 companies	92.3%
	Miscellaneous 2 companies	7.7%

Robyn Karnauskas of Truist Financial specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 13 companies	50.0%
PHARMACEUTICAL PREPARATIONS 5 companies	19.2%
LARGE CAP PHARMA 4 companies	15.4%
MED - DRUGS 2 companies	7.7%
Miscellaneous 2 companies	7.7%

Robyn Karnauskas' Ratings History at Truist Financial

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
TRML Tourmaline Bio	9/10/2025	Downgrade	$47.64	$48.00	Hold	$0.00 00.00% ROI
ABCL AbCellera Biologics	5/16/2025	Lower Price Target	$2.04	$10.00	Buy	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.